Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7387709 | 0.93 | KMT2A (0.74) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 | |
| SCHEMBL7539835 | 0.93 | KMT2A (0.74) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 | |
| SCHEMBL6313636 | 0.92 | KMT2A (0.72) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 | |
| SCHEMBL23778358 | 0.91 | KMT2A (0.70) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 | |
| SCHEMBL1625323 | 0.89 | KMT2A (0.68) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 | |
| SCHEMBL4878379 | 0.89 | KMT2A (0.68) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 | |
| SCHEMBL11860514 | 0.89 | KMT2A (0.64) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 | |
| SCHEMBL11814914 | 0.88 | KMT2A (1.00) | KMT2ASLC6A4OPRM1SLC6A2SLC6A3 | |
| SCHEMBL2288239 | 0.88 | KMT2A (0.67) | KMT2AKDM1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3249332 | 0.88 | KMT2A (0.67) | KMT2AKDM1ASLC6A4OPRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9296745-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2834238-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | Pfizer Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150416-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1957495-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | GRK6, FGFR1, PTK6 | KMT2A 186/4885KDM1A 769/4885SLC6A4 568/4885 |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | KMT2A 770/4885KDM1A 2286/4885SLC6A4 1953/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | KMT2A 1121/4885KDM1A 996/4885SLC6A4 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.